Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer

Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer Peter Kozuch, Michael L. Grossbard, Atis Barzdins, Miguel Araneo, Abigail Robin, David Frager, Peter Homel, Jennifer Marino, Paola DeGregorio, H.W. Bruckner Oncologist 2001; 6: 488-495 Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in gastrointestinal cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify activity and survival outcomes associated with single-agent gemcitabine as first-line therapy for patients with metastatic pancreatic cancer. Identify palliative treatment options for patients with metastatic pancreatic cancer upon disease progression with gemcitabine. Identify development of two to four drug gemcitabine-based combinations as an encouraging research priority. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 16, 2005 Most Recent Review: Mar. 16, 2005* Most Recent Update: Mar. 16, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.